Bioasis Technologies Inc. announced the appointment of Dr. May Orfali to the position of Consultant Chief Medical Officer, effective immediately. In this position, Dr. Orfali replaces Dr. Jose Iglesias, who has recently accepted a full-time position at another company. Dr. May Orfali has a deep and extensive background in drug and clinical development programs that spans two decades in multiple therapeutic areas, with a focus on rare diseases, oncology, hematology, infectious disease and women’s health. Her most recent role was President at Oncology and Rare disease Consulting, LLC, she was the Chief Medical Officer at CANbridge Life Sciences where she led the clinical development and medical affairs group, focused on progressing phase 1 and phase II oncology assets in glioblastoma multiforme and esophageal cancer, filing NDA for neratinib in China in adjuvant and metastatic breast cancer therapy. Dr. Orfali has also spent several years at Pfizer as Global Medical Lead and Executive Director, Global Product Development across multiple rare disease assets in hematology, sickle cell disease, hemophilia, endocrinology, gene therapy and TTR-amyloidosis. Prior to her time at Pfizer, Dr. Orfali held several clinical leadership positions, at Wyeth, Artisan Pharma, Aeris Therapeutics, Cubist Pharmaceuticals and Boston Scientific Corporation.